tldrdailynews.com logo

Pfizer's Braftovi Significantly Extends Survival in Advanced Colorectal Cancer

1 min read
Source: NBC News
Pfizer's Braftovi Significantly Extends Survival in Advanced Colorectal Cancer
Photo: NBC News
TL;DR

A late-stage trial found that a Pfizer combination therapy, including chemotherapy, cetuximab, and Braftovi, doubled survival time for patients with aggressive colorectal cancer with BRAF V600E mutation, setting a new standard of care for this subset of patients.

Topics:businesshealth#braf-mutation#colon-cancer#combination-therapy#health#pfizer#survival-rate
Share this article
  1. Advanced colon cancer patients lived twice as long with a Pfizer combo therapy, trial finds  NBC News
  2. ASCO25: Pfizer's Braftovi confers 'unprecedented' survival benefit in CRC  FirstWord Pharma
  3. Pfizer’s Braftovi Doubles Survival in Advanced Colorectal Cancer  Bloomberg.com
  4. Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer  Yahoo Finance
  5. ASCO: Pfizer, chasing full approval conversion for Braftovi combo, touts 'unprecedented' survival win  Fierce Pharma

Want the full story? Read the original reporting

Read on NBC News